In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Genzyme nets $11.2M in IPO spinoff 33% of Genzyme Transgenics

Executive Summary

Genzyme has spun off 33% of its Genzyme Transgenics division (producing complex proteins in the milk of transgenic animals) in an initial public offering of 1.5 million common shares at $8 per share, raising net proceeds of $11.2 million.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
    • Transgenics
Deal Status
  • Final
Deal Type
  • Financing
    • IPO
    • Spin-Off

Related Companies